You are here: Industry Insights > Market News > Unichem Laboratories gets USFDA approval for Apremilast Tablets

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Unichem Laboratories gets USFDA approval for Apremilast Tablets

expresspharmaFebruary 20, 2021

Tag: Unichem , FDA , Apremilast

Favorites

Unichem Laboratories has received ANDA approval for its Apremilast Tablets, 10 mg, 20 mg and 30 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Amgen’s Otezla (apremilast) Tablets, 10 mg, 20 mg, and 30 mg.

Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

Previous:Zydus Cadila gets final nod from USFDA for Droxidopa Capsules

Next:Eli Lilly enters into $960 million deal with Rigel Pharma to develop autoimmune therapy

New CRO Focused on Cannabis-based Drug Trials Launched

Biotech NewswireMay 23, 2024

Cannovation Clinical Research Partners takes a holistic approach to assist businesses throughout the entire product lifecycle, encompassing product development, commercialization, and launch phases.

InnoCare Announces First Patient Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

PharmaSourcesMay 21, 2024

Selection of Commercial Models for Innovative Drugs

PharmaSourcesMay 21, 2024

Unichem Laboratories gets USFDA approval for Apremilast Tablets | Pharmasources.com

Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA

Biotech NewswireMay 17, 2024

The expanded collaboration includes increasing adoption of the NVIDIA Clara suite of AI-powered computing platforms, software, and services in the Sartorius ecosystem.

Unichem Laboratories gets USFDA approval for Apremilast Tablets

Related News

New CRO Focused on Cannabis-based Drug Trials Launched

InnoCare Announces First Patient Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

Selection of Commercial Models for Innovative Drugs

Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA

You may like